"TAKE-HOME MESSAGE
Using SEER–Medicare data, this study compared survival outcomes and adverse effects associated with radical prostatectomy (RP) plus radiotherapy (XRT) versus XRT plus androgen deprivation therapy (ADT) in 13,856 men with cT3-T4N0M0 locally advanced (LAPCa) or cT3-T4N1M0 regionally advanced (RAPCa) prostate cancer. For patients who underwent RP plus XRT, 10-year prostate cancer–specific survival and 10-year overall survival rates were improved compared with those who underwent XRT plus ADT. Relative to patients receiving XRT plus ADT, rates of erectile dysfunction and urinary incontinence were higher in patients receiving RP plus XRT.
The study authors concluded that men with LAPCa or RAPCa treated initially with RP plus XRT had both reduced risk of prostate cancer–specific death and improved overall survival relative to men who were treated with XRT plus ADT."